Children’s Preferences for Oral Dosage Forms and Their Involvement in Formulation Research via EPTRI (European Paediatric Translational Research Infrastructure)
Elisa Alessandrini,
Francis Brako,
Mariagiovanna Scarpa,
Mariangela Lupo,
Donato Bonifazi,
Valeria Pignataro,
Maria Cavallo,
Ornela Cullufe,
Cristina Enache,
Begonya Nafria,
Joana Claverol,
Leen De Taeye,
Eric Vermeulen,
Jennifer Preston,
Catherine Tuleu
Affiliations
Elisa Alessandrini
Department of Pharmaceutics, University College London School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK
Francis Brako
Department of Pharmaceutics, University College London School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK
Mariagiovanna Scarpa
Department of Pharmaceutics, University College London School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK
Mariangela Lupo
TEDDY European Network of Excellence for Paediatric Research, via Luigi Porta 14, 27100 Pavia, Italy
Donato Bonifazi
Consorzio per Valutazioni Biologiche e Farmacologiche, CVBF, via N. Putignani 178, 70122 Bari, Italy
Valeria Pignataro
Consorzio per Valutazioni Biologiche e Farmacologiche, CVBF, via N. Putignani 178, 70122 Bari, Italy
Maria Cavallo
Consorzio per Valutazioni Biologiche e Farmacologiche, CVBF, via N. Putignani 178, 70122 Bari, Italy
Ornela Cullufe
Consorzio per Valutazioni Biologiche e Farmacologiche, Dege e Shoqerise se Huaj, CVBF Albania, Rr.Prokop Myzeqari, 1000 Tirana, Albania
Cristina Enache
The Romanian Angel Appeal Foundation, Strada Rodiei, 030956 București, Romania
Begonya Nafria
Sant Joan de Déu Research Institute, Esplugues de Llobregat, 08950 Barcelona, Spain
Joana Claverol
Sant Joan de Déu Research Institute, Esplugues de Llobregat, 08950 Barcelona, Spain
Leen De Taeye
Department of Internal Medicine and Paediatrics, Ghent University, 9000 Ghent, Belgium
Eric Vermeulen
Dutch Patient Alliance for Rare and Genetic Diseases, VSOP, Koninginnelaan 23, 3762 DA Soest, The Netherlands
Jennifer Preston
Department of Women’s and Children’s Health, Institute of Life Course and Medical Sciences, Alder Hey Children’s NHS Foundation Trust, Eaton Rd, Liverpool, L12 2AP, UK
Catherine Tuleu
Department of Pharmaceutics, University College London School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK
The paucity of evidence-based data on formulation characteristics preferred by the children is known to limit the design of tailored paediatric dosage forms. The European Paediatric Translational Research Infrastructure (EPTRI) commissioned a study to evaluate children’s dosage forms perceived preferences in some European countries and explore the feasibility of using the young persons advisory groups (YPAGs) to involve children in formulation research. An online, age-adapted survey was developed and translated into six languages. The survey link was disseminated across seven European countries: Albania, Italy, the Netherlands, and Dutch-speaking part of Belgium, Romania, Spain, and the United Kingdom. Respondents’ (n = 1172) perceived preferences for oral dosage forms primarily differed based on age, health status, and experience. Conventional dosage forms, i.e., liquid (35%), tablets (19%), and capsules (14%), were the most selected. Liquid was widely selected by children less than 12 years and by those healthy and taking medicines rarely. Monolithic solid forms were mostly chosen by adolescents and by children with a chronic disease taking medicines frequently. There was a clear lack of familiarity with more novel dosage forms (e.g., orodispersible films and granules). Noteworthy, granules were not appreciated, particularly by adolescents (52.8%). To rationalise the creation of paediatric formulations, it is important to involve children as active stakeholders and to apply tools assessing children’s perspectives on medicines to inform acceptable dosage form development from the start.